Treatment with FIS led to a significant increase in the expression of Bax and a decrease in the expression of Bcl-2, along with a significant increase in the expression of caspase-3, caspase-9, and cytochrome c in mice with lung cancer [170]. The gene discussed is BCL2; the disease is lung carcinoma.